ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,172.15
0.63%
Dow Jones
38,225.66
0.85%
Gold vs US Dollar
2,307.995
0.19%
Brent Oil
83.825
0.23%
Bitcoin
59,611.74
0.83%
Pepperstone
Advertisement
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. Europe
  5. EU
  6. Ab Science (AB)

  7. Ab Science (AB) News

Ab Science (AB)

Ab Science
Date:
Sort by:
 Showing the most relevant articles for your search:EU:AB
DateTimeSourceHeadlineSymbolCompany
02/05/202418:14GlobeNewswire Inc.AB Science : La Cour d’Appel de Paris confirme la mise hors de cause du Président Directeur Général d’AB Science, Alain Moussy, et diminue le montant de la sanction imposée à AB ScienceEU:ABAb Science
02/05/202418:14GlobeNewswire Inc.AB Science : The Paris Court of Appeal confirms the acquittal of the CEO of AB Science, Alain Moussy, and reduces the amount of the financial penalty imposed on AB ScienceEU:ABAb Science
02/05/202418:14GlobeNewswire Inc.AB Science : The Paris Court of Appeal confirms the acquittal of the CEO of AB Science, Alain Moussy, and reduces the amount of the financial penalty imposed on AB ScienceEU:ABAb Science
30/04/202417:56GlobeNewswire Inc.AB Science announces a slight delay in the publication of its 2023 annual financial reportEU:ABAb Science
30/04/202417:56GlobeNewswire Inc.AB Science annonce un léger décalage de la publication de son rapport financier annuel 2023EU:ABAb Science
30/04/202417:56GlobeNewswire Inc.AB Science announces a slight delay in the publication of its 2023 annual financial reportEU:ABAb Science
03/04/202417:08GlobeNewswire Inc.AB Science announces that Health Canada has granted eligibility for reconsideration request for masitinib in ALSEU:ABAb Science
03/04/202417:08GlobeNewswire Inc.AB Science annonce que Santé Canada a jugé admissible la demande de réexamen du masitinib dans SLAEU:ABAb Science
13/03/202411:58GlobeNewswire Inc.AB Science : De nouvelles recherches montrent que le masitinib limite les dommages neuronaux dans un modèle de maladie neurodégénérative d’origine neuroimmuneEU:ABAb Science
13/03/202411:58GlobeNewswire Inc.AB Science: New research shows that masitinib limits neuronal damage in a model of neuroimmune-driven neurodegenerative diseaseEU:ABAb Science
13/03/202411:58GlobeNewswire Inc.AB Science: New research shows that masitinib limits neuronal damage in a model of neuroimmune-driven neurodegenerative diseaseEU:ABAb Science
07/03/202414:20GlobeNewswire Inc.AB Science propose un résumé de la conférence virtuelle qui s’est tenue le 4 mars 2024, avec pour objectif de faire le point sur le développement d'AB ScienceEU:ABAb Science
07/03/202414:20GlobeNewswire Inc.AB Science provides a summary of the live webcast held on March 4, 2024 giving an update on AB Science developmentEU:ABAb Science
07/03/202414:20GlobeNewswire Inc.AB Science provides a summary of the live webcast held on March 4, 2024 giving an update on AB Science developmentEU:ABAb Science
06/03/202419:21GlobeNewswire Inc.AB Science announces that two financial analysis firms, DNA Finance and In Extenso Finance, have initiated coverage of the CompanyEU:ABAb Science
06/03/202419:21GlobeNewswire Inc.AB Science annonce l’initiation de la couverture de son titre par deux sociétés d’analyse financières, DNA Finance d’une part, et par In Extenso Finance d’autre partEU:ABAb Science
06/03/202419:21GlobeNewswire Inc.AB Science announces that two financial analysis firms, DNA Finance and In Extenso Finance, have initiated coverage of the CompanyEU:ABAb Science
01/03/202417:07GlobeNewswire Inc.AB Science tiendra une conférence virtuelle le lundi 4 mars 2024, de 18h30 à 19h30EU:ABAb Science
01/03/202417:07GlobeNewswire Inc.AB Science will host a live webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CETEU:ABAb Science
01/03/202417:07GlobeNewswire Inc.AB Science will host a live webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CETEU:ABAb Science
29/02/202410:49GlobeNewswire Inc.AB Science will host a live webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CETEU:ABAb Science
29/02/202410:49GlobeNewswire Inc.AB Science tiendra une conférence virtuelle le lundi 4 mars 2024, de 18h30 à 19h30EU:ABAb Science
29/02/202410:49GlobeNewswire Inc.AB Science will host a live webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CETEU:ABAb Science
26/02/202417:32GlobeNewswire Inc.AB Science announces that Health Canada has issued a Notice of Non-Compliance-Withdrawal (NON/w) for masitinib in ALSEU:ABAb Science
26/02/202417:32GlobeNewswire Inc.AB Science annonce que Santé Canada a émis un Avis de Non-Conformité-Retrait (ANC-R) pour le masitinib dans la SLAEU:ABAb Science
26/02/202417:32GlobeNewswire Inc.AB Science announces that Health Canada has issued a Notice of Non-Compliance-Withdrawal (NON/w) for masitinib in ALSEU:ABAb Science
26/01/202417:01GlobeNewswire Inc.AB Science announces an update in the marketing authorization application of masitinib in amyotrophic lateral sclerosis at the European Medicines AgencyEU:ABAb Science
26/01/202417:01GlobeNewswire Inc.AB Science fait le point sur la demande d’autorisation de mise sur le marché du masitinib dans la sclérose latérale amyotrophique auprès de l’Agence Européenne des MédicamentsEU:ABAb Science
26/01/202417:01GlobeNewswire Inc.AB Science announces an update in the marketing authorization application of masitinib in amyotrophic lateral sclerosis at the European Medicines AgencyEU:ABAb Science
15/01/202417:06GlobeNewswire Inc.AB Science reçoit un avis d’acceptation pour le brevet européen couvrant le masitinib jusqu’en 2036 dans le traitement de la mastocytoseEU:ABAb Science
 Showing the most relevant articles for your search:EU:AB

Your Recent History

LSE
MIN
Minoan
LSE
BARC
Barclays
LSE
TERN
Tern
LSE
BOO
Boohoo
LSE
GKP
Gulf Keystone Petroleum
LSE
FEVR
Fevertree Drinks
LSE
ENET
Ethernity Networks
LSE
GENF
Genflow Biosciences
LSE
TSCO
Tesco
LSE
PTAL
Petrotal
LSE
INSP
Inspirit Energy
LSE
ASC
Asos
LSE
LLOY
Lloyds Banking
LSE
FUM
Futura Medical
LSE
DGI
Dg Innovate
LSE
GLEN
Glencore
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved